These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37753246)

  • 21. Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes.
    Haensli C; Pfister IB; Garweg JG
    J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34204266
    [No Abstract]   [Full Text] [Related]  

  • 22. Brolucizumab in Neovascular Age-Related Macular Degeneration - Indian Real-World Experience: The BRAILLE Study - Fifty-Two-Week Outcomes.
    Chakraborty D; Maiti A; Sheth JU; Mondal S; Boral S; Nandi K; Sinha TK; Das A
    Clin Ophthalmol; 2022; 16():4303-4313. PubMed ID: 36583092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SHORT-TERM OUTCOMES AFTER INTERIM TREATMENT WITH BROLUCIZUMAB: A Retrospective Case Series of a Single Center Experience.
    Awh CC; Davis EC; Thomas MK; Thomas AS
    Retina; 2022 May; 42(5):899-905. PubMed ID: 35067611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab.
    Zubricky R; McCoy J; Donkor R; Miller DG; Sonbolian N; Heaney A; Bilano V; Karcher H; Coney JM
    Ophthalmol Ther; 2023 Oct; 12(5):2397-2408. PubMed ID: 37310683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK.
    Ogura Y; Jaffe GJ; Cheung CMG; Kokame GT; Iida T; Takahashi K; Lee WK; Chang AA; Monés J; D'Souza D; Weissgerber G; Gedif K; Koh A
    Br J Ophthalmol; 2022 Jul; 106(7):994-999. PubMed ID: 34301613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brolucizumab for pre-treated patients with choroidal neovascularization and signs of tachyphylaxis to aflibercept and bevacizumab.
    Boltz A; Radunsky K; Weingessel B; Vécsei-Marlovits VP
    Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2561-2566. PubMed ID: 35348844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients.
    Mishra SK; Kumar P; Khullar S; Joshi A; Sati A; Kumar SV; Unni D; Kumar A
    Int J Retina Vitreous; 2022 Jul; 8(1):51. PubMed ID: 35902887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.
    Jaffe GJ; Martin DF; Toth CA; Daniel E; Maguire MG; Ying GS; Grunwald JE; Huang J;
    Ophthalmology; 2013 Sep; 120(9):1860-70. PubMed ID: 23642377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brolucizumab for Neovascular Age-Related Macular Degeneration (BEL Study).
    Van Cleemput L; Peeters F; Jacob J
    Clin Ophthalmol; 2023; 17():1077-1085. PubMed ID: 37064958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration.
    Ota H; Takeuchi J; Nakano Y; Horiguchi E; Taki Y; Ito Y; Terasaki H; Nishiguchi KM; Kataoka K
    Jpn J Ophthalmol; 2022 May; 66(3):278-284. PubMed ID: 35233693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World Safety Outcomes with Brolucizumab in Neovascular Age-Related Macular Degeneration: Findings from the IRIS® Registry.
    Zarbin MA; MacCumber MW; Karcher H; Adiguzel E; Mayhook A; LaPrise A; Bilano VL; Igwe F; Ip MS; Wykoff CC
    Ophthalmol Ther; 2024 May; 13(5):1357-1368. PubMed ID: 38520643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of adverse events after loading phase of the brolucizumab therapy of neovascular AMD: Real-life evidence in the Czech Republic.
    Stepanov A; Studnicka J; Veith M; Nemec P; Vyslouzilova D; Koubek M; Nemcansky J
    Eur J Ophthalmol; 2022 Oct; ():11206721221132619. PubMed ID: 36254407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meticulous multimodal analysis of aflibercept therapy for submacular vascularized pigment epithelial detachment associated with neovascular AMD in a prospective case series, the EVEN study.
    Chan CK; Sarraf D; Abraham P; Lalezary M; Lin SG; Chen X; Nittala MG; Sadda S
    Am J Ophthalmol Case Rep; 2020 Dec; 20():100916. PubMed ID: 33024885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
    Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-Life Experience and Predictors of Visual Outcomes with Intravitreal Brolucizumab Switch for Treatment of Neovascular Age-Related Macular Degeneration.
    Cavalleri M; Tombolini B; Sacconi R; Gatta G; Valeri R; Bandello F; Querques G
    Ophthalmologica; 2023; 246(2):158-168. PubMed ID: 37040734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EFFECT OF RANIBIZUMAB AND AFLIBERCEPT ON RETINAL PIGMENT EPITHELIAL DETACHEMENT, SUBRETINAL AND INTRARETINAL FLUID IN AGE-RELATED MACULAR DEGENERATION.
    Sumarová P; Ovesná P; Matušková V; Beránek J; Michalec M; Michalcová L; Autrata D; Vysloužilová D; Chrapek O
    Cesk Slov Oftalmol; 2022; 78(4):176-185. PubMed ID: 35922146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Brolucizumab and Aflibercept on the Maximum Thickness of Pigment Epithelial Detachments and Sub-Retinal Pigment Epithelium Fluid in HAWK and HARRIER.
    Khanani AM; Sadda SR; Sarraf D; Tadayoni R; Wong DT; Kempf AS; Saffar I; Gedif K; Chang A
    Ophthalmol Retina; 2024 Jul; ():. PubMed ID: 39033924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-Dose Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration Resistant to Standard-Dose Brolucizumab.
    Kim J; Park MS; Cho BJ; Kwon S
    Ophthalmol Ther; 2024 Oct; 13(10):2789-2797. PubMed ID: 39214946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab.
    Baumal CR; Spaide RF; Vajzovic L; Freund KB; Walter SD; John V; Rich R; Chaudhry N; Lakhanpal RR; Oellers PR; Leveque TK; Rutledge BK; Chittum M; Bacci T; Enriquez AB; Sund NJ; Subong ENP; Albini TA
    Ophthalmology; 2020 Oct; 127(10):1345-1359. PubMed ID: 32344075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brolucizumab for Wet Age-Related Macular Degeneration: One-Year Real-World Experience from a Tertiary Center.
    Scupola A; Carlà MM; Boselli F; Giannuzzi F; De Filippis A; Fossataro C; Minnella AM; D'Amico G; Coppola G; Savastano MC; Sammarco MG; Rizzo S
    Ophthalmologica; 2023; 246(1):58-67. PubMed ID: 36843038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.